| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $2,504,199 | 14 | 93 |
Sells | $22,478 | 1 | 7 |
| Mosseri Marlio Charles | 10 percent owner | 11 | $2.37M | 0 | $0 | $2.37M |
| BENTSUR RON | Chairman & CEO | 2 | $119,325 | 0 | $0 | $119,325 |
| Poradosu Enrique | Chief Science & Business Off | 1 | $9,980 | 0 | $0 | $9,980 |
| Carson Michael J. | Vice President, Finance | 0 | $0 | 1 | $22,478 | $-22,478 |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Over the last 12 months, insiders at Nuvectis Pharma, Inc. have bought $2.5M and sold $22,478 worth of Nuvectis Pharma, Inc. stock.
On average, over the past 5 years, insiders at Nuvectis Pharma, Inc. have bought $2.44M and sold $22,478 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mosseri Marlio Charles (10 percent owner) — $2.37M. BENTSUR RON (Chairman & CEO) — $119,325. Poradosu Enrique (Chief Science & Business Off) — $9,980.
The last purchase of 5,603 shares for transaction amount of $44,768 was made by Mosseri Marlio Charles (10 percent owner) on 2025‑06‑20.
| 2025-06-20 | Mosseri Marlio Charles | 10 percent owner | 5,603 0.0264% | $7.99 | $44,768 | -4.98% | ||
| 2025-06-18 | Mosseri Marlio Charles | 10 percent owner | 28,043 0.1342% | $8.05 | $225,746 | -3.85% | ||
| 2025-06-17 | Mosseri Marlio Charles | 10 percent owner | 5,399 0.0258% | $8.11 | $43,786 | -3.58% | ||
| 2025-05-12 | Mosseri Marlio Charles | 10 percent owner | 21,167 0.0866% | $8.11 | $171,664 | +5.24% | ||
| 2025-05-09 | Mosseri Marlio Charles | 10 percent owner | 25,062 0.1054% | $8.94 | $223,965 | -2.84% | ||
| 2025-05-08 | Mosseri Marlio Charles | 10 percent owner | 2,600 0.0107% | $8.96 | $23,298 | -4.23% | ||
| 2025-05-07 | Mosseri Marlio Charles | 10 percent owner | 12,317 0.0516% | $8.59 | $105,770 | +0.80% | ||
| 2025-05-06 | Mosseri Marlio Charles | 10 percent owner | 12,444 0.051% | $8.59 | $106,955 | -1.45% | ||
| 2025-02-07 | Mosseri Marlio Charles | 10 percent owner | 240,000 0.8579% | $5.00 | $1.2M | +29.66% | ||
| 2024-12-24 | BENTSUR RON | Chairman & CEO | 4,500 0.0233% | $4.65 | $20,925 | +74.95% | ||
| 2024-12-13 | Mosseri Marlio Charles | 10 percent owner | 17,000 0.0872% | $4.70 | $79,900 | +70.21% | ||
| 2024-12-12 | Mosseri Marlio Charles | 10 percent owner | 32,121 0.1662% | $4.64 | $149,041 | +72.20% | ||
| 2024-11-19 | Poradosu Enrique | Chief Science & Business Off | 2,000 0.0103% | $4.99 | $9,980 | +50.58% | ||
| 2024-11-15 | BENTSUR RON | Chairman & CEO | 20,000 0.0887% | $4.92 | $98,400 | +56.06% | ||
| 2024-11-07 | Sale | Carson Michael J. | Vice President, Finance | 2,755 0.0146% | $8.16 | $22,478 | -7.19% | |
| 2024-05-14 | BENTSUR RON | Chairman & CEO | 1,940 0.0105% | $6.74 | $13,076 | -1.85% | ||
| 2024-05-10 | BENTSUR RON | Chairman & CEO | 2,000 0.0109% | $6.40 | $12,800 | +3.59% | ||
| 2024-05-10 | Poradosu Enrique | Chief Science & Business Off | 500 0.0027% | $6.29 | $3,145 | +3.59% | ||
| 2024-05-10 | Shemesh Shay | Chief Dev. & Ops. Officer | 1,113 0.006% | $6.32 | $7,034 | +3.59% | ||
| 2024-03-18 | BENTSUR RON | Chairman & CEO | 5,000 0.0283% | $10.29 | $51,450 | -37.18% |
| BENTSUR RON | Chairman & CEO | 3270924 15.6552% | $25.77M | 55 | 0 | <0.0001% |
| Mosseri Marlio Charles | 10 percent owner | 2981806 14.2714% | $23.5M | 30 | 0 | <0.0001% |
| Poradosu Enrique | Chief Science & Business Off | 1506319 7.2095% | $11.87M | 6 | 0 | +21.81% |
| Carson Michael J. | Vice President, Finance | 87918 0.4208% | $692,793.84 | 0 | 1 | |
| Shemesh Shay | Chief Dev. & Ops. Officer | 1493068 7.1461% | $11.77M | 13 | 0 | +26.14% |
| Hoberman Kenneth | 55140 0.2639% | $434,503.20 | 1 | 0 | <0.0001% | |
| Kaplan Matthew L. | 35760 0.1712% | $281,788.80 | 1 | 0 | <0.0001% |
$22,617,831 | 95 | 3.32% | $158.86M | |
Nuvectis Pharma, Inc. (NVCT) | $7,237,838 | 92 | -8.14% | $164.64M |
$17,468,215 | 46 | 18.85% | $155.67M | |
$140,938,207 | 36 | 14.75% | $193.56M | |
$18,752,549 | 33 | -28.39% | $159.06M | |
$41,069,367 | 23 | 54.64% | $197.49M | |
$178,593,887 | 15 | -14.86% | $163.2M | |
$15,799,576 | 12 | -39.52% | $204.8M | |
$13,043,783 | 8 | 732.82% | $156.5M | |
$145,296,407 | 8 | -0.98% | $193.12M | |
$17,675,244 | 7 | 92.20% | $168.27M | |
$22,090,972 | 7 | -3.49% | $157.11M | |
$45,000,000 | 6 | -31.22% | $160.65M | |
$88,549,962 | 5 | -16.91% | $198.27M | |
$556,839 | 5 | 13.42% | $158.35M | |
$32,289,200 | 3 | -5.46% | $160.99M | |
$40,000,000 | 3 | -16.24% | $194.98M | |
$149,309 | 3 | 6.07% | $169.16M | |
$20,020,000 | 1 | -75.24% | $174.17M |
| Increased Positions | 23 | +74.19% | 907,869 | +68.55% |
| Decreased Positions | 12 | -38.71% | 185,171 | -13.98% |
| New Positions | 10 | New | 460,441 | New |
| Sold Out Positions | 9 | Sold Out | 91,402 | Sold Out |
| Total Postitions | 42 | +35.48% | 2M | +54.57% |
| Baldwin Wealth Partners Llc/Ma | $3,316.00 | 1.56% | 358,461 | +2,500 | +0.7% | 2025-03-31 |
| Vanguard Group Inc | $3,009.00 | 1.41% | 325,297 | +24,159 | +8.02% | 2024-12-31 |
| Iridian Asset Management Llc/Ct | $2,349.00 | 1.1% | 253,972 | +253,972 | New | 2025-03-31 |
| Marshall Wace, Llp | $1,152.00 | 0.54% | 124,571 | +81,757 | +190.96% | 2024-12-31 |
| Geode Capital Management, Llc | $733.00 | 0.35% | 79,243 | -473 | -0.59% | 2024-12-31 |
| Blackrock, Inc. | $633.00 | 0.3% | 68,484 | +6,142 | +9.85% | 2025-03-31 |
| Forbes J M & Co Llp | $546.00 | 0.26% | 59,000 | +10,599 | +21.9% | 2024-12-31 |
| Susquehanna International Group, Llp | $422.00 | 0.2% | 45,607 | +19,144 | +72.34% | 2024-12-31 |
| Oppenheimer & Co Inc | $379.00 | 0.18% | 41,000 | +16,000 | +64% | 2025-03-31 |
| Austin Wealth Management, Llc | $372.00 | 0.18% | 40,250 | +40,250 | New | 2025-03-31 |